BridgeBio Pharma Total Non-Operating Income/Expense 2018-2025 | BBIO

BridgeBio Pharma total non-operating income/expense for the twelve months ending March 31, 2025 was $0.022B, a 133.5% decline year-over-year.

  • BridgeBio Pharma annual total non-operating income/expense for 2024 was $0.051B, a 210.68% decline from 2023.
  • BridgeBio Pharma annual total non-operating income/expense for 2023 was $-0.046B, a 266.54% decline from 2022.
  • BridgeBio Pharma annual total non-operating income/expense for 2022 was $0.028B, a 380.49% decline from 2021.

BridgeBio Pharma Total Non-Operating Income/Expense 2018-2025 | BBIO

  • BridgeBio Pharma annual total non-operating income/expense for 2024 was $0.051B, a 210.68% decline from 2023.
  • BridgeBio Pharma annual total non-operating income/expense for 2023 was $-0.046B, a 266.54% decline from 2022.
  • BridgeBio Pharma annual total non-operating income/expense for 2022 was $0.028B, a 380.49% decline from 2021.